Monitoring neoadjuvant chemotherapy of breast cancer using 3D subharmonic aided pressure estimation

项目摘要 新辅助化疗（NAC）是治疗局部晚期乳腺癌的标准治疗方法 （LABC）。在手术前应用这种系统性治疗可提高患者的 保乳手术，化疗反应的早期指征，以及改善的结果， 高危患者的某些亚组。对NAC的临床反应与病理结果相关 在手术时和手术后的存活率。此外，重要的是要在早期识别无应答者。 治疗过程，以节省他们不必要的费用和无效治疗的副作用，如 恶心、脱发、血液学毒性、神经毒性（如紫杉烷类）或心脏毒性（如蒽环类）。它 也有报道称，对初始新辅助治疗方案无反应但对新辅助治疗方案有反应的患者的存活率 不同的第二新辅助治疗方案的应答者的存活率与初始治疗方案的应答者的存活率相似。因此，在本发明中， 早期评估乳腺癌对NAC的反应可以通过早期治疗来改善患者的生存率 修改，并可能加快有效NAC给药的时间轴。最大的 监测NAC的一个挑战是在治疗的早期阶段量化反应。缓解评估 目前依赖于肿瘤缩小，但肿瘤大小的变化，即形态学变化，可以发生在肿瘤缩小之后。 功能和生理变化。因此，需要探索新的功能评估，以改善 早期治疗反应预测的准确性。间质流体压力（IFP）已被建议作为一个因素 影响治疗反应。IFP的增加阻止了治疗剂的有效摄取， 癌症治疗的有效性乳腺肿瘤的IFP可以直接使用吸液芯进行侵入性测量， 针刺技术然而，这种侵入性方法难以应用于患者，并且不是护理标准。我们 该小组提出了一种创新的超声技术，称为亚谐波辅助压力估计（SHAPE） 用于非侵入性IFP评估，最近进行了一项3D SHAPE监测治疗能力的试点研究 接受NAC治疗的女性的反应。本研究表明，肿瘤中的次谐波信号差异 相对于正常组织，可以早在施用仅10%的 治疗方案（即，1个NAC周期）。虽然令人鼓舞，但这项研究是基于有限的案例， 在一个机构。在这个项目中，我们建议将学术界和工业界的研究人员聚集在一起， 目的是进行多中心临床评价，以验证先前的研究结果。我们的假设是 肿瘤相对于正常组织的次谐波信号差异可以预测乳腺癌NAC反应 在10%的治疗方案后。

Project Abstract Neoadjuvant chemotherapy (NAC) is the standard of care for treatment of locally advanced breast cancer (LABC). Application of this systematic therapy before surgery benefits patients by providing improved rates of breast-conserving surgery, early indication of response to chemotherapy, as well as improved outcomes for certain subgroups of high-risk patients. The clinical response to NAC is correlated with the pathologic outcome at the time of surgery and post-surgery survival. Also, it is important to identify non-responders early in the course of treatment to save them from unnecessary cost and side effects of ineffective treatment, such as nausea, alopecia, haematological toxicity, neurotoxicity (e.g. taxanes) or cardiotoxicity (e.g. anthracyclines). It has also been reported that survival of patients not responding to an initial neoadjuvant regimen, but responding to a different second neoadjuvant regimen is similar to the survival of responders to the initial regimen. Thus, early assessment of breast cancer response to NAC can improve patients' survival by allowing for earlier therapy modification, and potentially accelerating the timeline to administration of an effective NAC. The biggest challenge in monitoring NAC is to quantify response at an early stage of therapy. Response assessment currently relies on tumor shrinkage, but the tumor size changes, i.e. morphologic changes, can happen later than functional and physiologic changes. Thus, new functional assessments need to be explored to improve the accuracy of early therapy response prediction. Interstitial fluid pressure (IFP) has been suggested as a factor affecting therapeutic response. Increased IFP prevents an effective uptake of therapeutic agents and reduces the efficacy of cancer therapy. The IFP of breast tumors can be directly measured invasively using a wick-in- needle technique. However, this invasive method is difficult to apply in patients and not standard of care. Our group has proposed an innovative ultrasound technique called subharmonic-aided pressure estimation (SHAPE) for noninvasive IFP evaluation and recently conducted a pilot study of 3D SHAPE's ability to monitor treatment response in women undergoing NAC. This study showed that the subharmonic signal difference in the tumor relative to the normal tissue could predict treatment response as early as after administration of only 10% of therapy regimen (i.e., 1 cycle of NAC). While encouraging, this study was based on a limited number of cases at a single institution. In this project we propose to bring together researchers from academia and industry in order to conduct a multi-center clinical evaluation to validate previous findings. Our hypothesis is that the subharmonic signal difference in the tumor relative to the normal tissue can predict breast cancer NAC response after 10% of therapy regimen.